Overview

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III or IV, CDC classification).
Phase:
N/A
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Nystatin